The Melanocortin System: Melanotan, PT-141 & Alpha-MSH

The melanocortin system comprises five G-protein coupled receptors (MC1R–MC5R), each with distinct tissue distributions and functions:

MC1R — Pigmentation - Found on melanocytes (pigment-producing cells in the skin) - Activation stimulates eumelanin (dark pigment) production - Natural ligand: alpha-MSH - Genetic variants in MC1R are the primary determinant of hair and skin colour

MC2R — Adrenal Function - Located on adrenal cortex cells - Exclusively activated by ACTH (adrenocorticotrophic hormone) - Controls cortisol production - Not targeted by recreational melanocortin peptides

MC3R — Energy Homeostasis - Expressed in the hypothalamus and gut - Involved in energy balance and nutrient partitioning - Modulates feeding behaviour alongside MC4R

MC4R — Appetite and Sexual Function - Hypothalamic expression — key regulator of appetite and satiety - Also mediates erectile function through spinal and supraspinal pathways - Loss-of-function MC4R mutations are the most common monogenic cause of obesity - The primary target for PT-141's sexual function effects

MC5R — Exocrine Function - Found in sebaceous glands and other exocrine tissues - Involved in sebum production and pheromone signalling in animals - Least studied of the five subtypes

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid peptide derived from the precursor protein proopiomelanocortin (POMC).

POMC processing: POMC is a remarkable precursor protein that is cleaved into multiple bioactive peptides depending on the tissue: - Anterior pituitary: Produces ACTH (which can be further cleaved to alpha-MSH) - Hypothalamus: Produces alpha-MSH and beta-endorphin - Skin: Local POMC processing produces alpha-MSH for paracrine pigmentation signalling

Alpha-MSH functions: - Binds MC1R on melanocytes → stimulates melanin synthesis - Binds MC3R/MC4R in the hypothalamus → reduces appetite - Exerts anti-inflammatory effects through multiple pathways - Modulates immune cell function (macrophages, neutrophils)

UV exposure connection: Ultraviolet radiation increases POMC expression in keratinocytes, leading to increased local alpha-MSH production. This is the molecular basis of tanning — UV exposure triggers a signalling cascade that ultimately stimulates melanocytes to produce more melanin.

Synthetic melanocortin peptides like melanotan II were designed to mimic and amplify this natural process.

Melanotan II is a cyclic heptapeptide analogue of alpha-MSH, originally developed at the University of Arizona in the 1990s.

Pharmacology: - Non-selective agonist — activates MC1R, MC3R, MC4R, and MC5R - Cyclic structure confers resistance to enzymatic degradation - Much longer half-life than natural alpha-MSH - Administered subcutaneously

Effects attributable to receptor subtypes: - MC1R activation → Tanning: Stimulates melanogenesis independently of UV exposure - MC4R activation → Sexual arousal: Produces pro-erectile effects in males and increased arousal in females - MC4R activation → Appetite suppression: Reduced hunger is commonly reported - MC3R/MC4R → Nausea: A frequently reported side effect, likely mediated through central melanocortin pathways

Why non-selectivity matters: Because melanotan II activates multiple receptor subtypes, users experience a range of effects — both desired (tanning, libido) and undesired (nausea, facial flushing, mole darkening). The mole-darkening effect is a particular safety concern, as it can mask early melanoma changes.

Regulatory status: Melanotan II is not approved by the MHRA, FDA, or any major regulatory body. The TGA (Australia) and MHRA (UK) have issued specific warnings against its use.

PT-141 (bremelanotide) was developed from melanotan II research when scientists noticed the sexual arousal effects and sought to isolate them from the pigmentation effects.

Key differences from melanotan II: - Linear peptide (not cyclic) — a metabolite of melanotan II - Greater selectivity for MC4R over MC1R - Minimal tanning effect at therapeutic doses - FDA-approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women

Mechanism of sexual function: Unlike PDE5 inhibitors (e.g., sildenafil) that work on vascular smooth muscle, PT-141 acts centrally: - Activates MC4R in the hypothalamus and limbic system - Modulates dopaminergic and oxytocinergic pathways involved in sexual arousal - Affects desire and arousal rather than purely mechanical erectile function - This central mechanism is why it works in both males and females

Clinical evidence: - Vyleesi approval was based on two Phase 3 trials (RECONNECT studies) - Statistically significant improvement in sexual desire scores vs placebo - Common side effects: nausea (40%), flushing, headache - The nausea led to an FDA recommendation to limit use to no more than once daily

PT-141 represents a notable example of melanocortin research yielding an approved pharmaceutical product.

The melanocortin system's broad physiological reach means that peptides targeting it carry specific safety considerations:

Pigmentation risks: - Darkening of existing moles and naevi — makes dermatological monitoring more difficult - New pigmented lesions may appear - The MHRA specifically warns that melanotan II could mask early signs of melanoma - Anyone with a personal or family history of melanoma should avoid melanocortin agonists

Cardiovascular considerations: - MC4R activation can transiently increase blood pressure - PT-141's FDA label includes a warning about blood pressure elevation - Individuals with uncontrolled hypertension or cardiovascular disease should exercise particular caution

Emerging melanocortin research: - Setmelanotide: An MC4R agonist approved for rare genetic obesity conditions (POMC deficiency, LEPR deficiency) - Anti-inflammatory applications: Alpha-MSH analogues are being investigated for inflammatory bowel disease and other inflammatory conditions - Neuroprotection: MC4R agonists show promise in preclinical stroke and neurodegeneration models

The broader lesson: The melanocortin system illustrates a recurring theme in peptide pharmacology — receptors with overlapping tissue distributions make truly selective targeting difficult. The evolution from non-selective melanotan II to more selective PT-141 and setmelanotide demonstrates how pharmaceutical development aims to refine receptor selectivity to maximise benefit and minimise off-target effects.

*This article is for educational purposes only. Melanotan II is not approved by any major regulatory body. PT-141 (Vyleesi) is a prescription medication. Consult a healthcare professional before considering any melanocortin-targeting peptide.*